Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 23;190(5):66.
doi: 10.1007/s11046-025-00977-z.

Topical Luliconazole Treatment for Hyperkeratotic Tinea Pedis

Sayaka Ohara  1 , Hiromitsu Noguchi  2   3 , Tadahiko Matsumoto  4   5 , Daiki Hayashi  6 , Kayo Kashiwada-Nakamura  6 , Masahide Kubo  4 , Rui Kano  7 , Satoshi Fukushima  6
Affiliations

Topical Luliconazole Treatment for Hyperkeratotic Tinea Pedis

Sayaka Ohara et al. Mycopathologia. .

Abstract

Chronic hyperkeratotic tinea pedis is a treatment-resistant infection. We evaluated the efficacy of a 3-month course of topical 1% luliconazole in 21 hyperkeratotic tinea pedis patients. The diagnosis was confirmed through microscopy and culture. The lesion area was assessed monthly using a software program. Clinical responses were classified into five categories from "cured" to "no change." Among the isolates, one terbinafine-resistant T. rubrum strain was detected. The mean lesion area decreased significantly over 3 months, with an average improvement rate of 94.1% ± 12.7% and a cure rate of 61.9%. The mean amount of luliconazole used per foot was 27.5 ± 9.7 g monthly. The resistant case showed a partial improvement with topical luliconazole and was successfully treated with oral fosravuconazole. These findings suggest that 1% topical luliconazole is effective for treating hyperkeratotic tinea pedis.

Keywords: Fosravuconazole; Hyperkeratotic tinea pedis; Luliconazole; Terbinafine-resistance.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: This study was partially supported by funding from Iwaki Seiyaku Co., Ltd. The authors declare no other conflicts of interest. Ethics Approval: The study was approved by the Noguchi Dermatology Clinic ethics committee (approval No.49).

References

    1. Craddock LN, Schieke SM. Superficial fungal infection. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, Orringer JS, editors. Fitzpatrick’s dermatology in general medicine. 9th ed. New York: McGraw-Hill; 2019. p. 2925–87.
    1. Tanuma H. Pathogenesis and treatment of hyperkeratotic tinea pedis in Japan. Mycoses. 1999;42:21–8. - DOI - PubMed
    1. Mochizuki T, Tsuboi R, Iozumi K, Ishizaki S, Ushigami T, Ogawa Y, et al. Guidelines Committee of the Japanese Dermatological Association. Guidelines for the management of dermatomycosis (2019). J Dermatol. 2020;47:1343–73. - DOI - PubMed
    1. Watanabe S, Takahashi H, Nishikawa T, Takiuchi I, Higashi N, Nishimoto K, et al. Dose-finding comparative study of 2 weeks of luliconazole cream treatment for tinea pedis–comparison between three groups (1%, 0.5%, 0.1%) by a multi-center randomised double-blind study. Mycoses. 2007;50:35–40. - DOI - PubMed
    1. Koga H, Nanjoh Y, Makimura K, Tsuboi R. In vitro antifungal activities of luliconazole, a new topical imidazole. Med Mycol. 2009;47:640–7. - DOI - PubMed

Supplementary concepts

LinkOut - more resources